Comparative Pharmacology
Head-to-head clinical analysis: CAMPATH versus DEPOCYT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAMPATH versus DEPOCYT.
CAMPATH vs DEPOCYT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alemtuzumab is a recombinant humanized monoclonal antibody that binds to CD52, a cell surface antigen expressed on B and T lymphocytes, NK cells, monocytes, and macrophages. Binding induces antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis, resulting in prolonged lymphocyte depletion.
Cytarabine is a nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and cell death in the S phase of the cell cycle.
12 mg/day intravenously over 2 hours, administered for 5 consecutive days (total 60 mg). For patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the recommended dose is 3 mg/day intravenously on day 1, 10 mg/day on day 2, and 30 mg/day on day 3 (dose escalation), followed by 30 mg/day three times per week on alternate days for up to 11 weeks (total cumulative dose up to 640 mg).
50 mg intrathecally via lumbar puncture or intraventricularly via Ommaya reservoir on days 1, 15, 29, 43, 57, 71, 85, and 99 for induction; followed by consolidation and maintenance doses. Administer with dexamethasone 4 mg PO/IV twice daily for 5 days starting on the day of DepoCyt injection.
None Documented
None Documented
Terminal half-life approximately 12 days (range 6-21 days) after repeated doses, supporting weekly dosing in CLL.
After intrathecal administration, the terminal half-life of cytarabine in CSF is 2.5-4.5 hours (mean 3.5 hours) due to slow clearance from CSF; systemic half-life is 10-15 minutes due to rapid deamination.
Clearance via opsonization and degradation in reticuloendothelial system; negligible renal or biliary excretion (<1% unchanged).
Renal excretion of cytarabine metabolites accounts for >70% of elimination; unchanged cytarabine excretion is minimal (<10%). Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Monoclonal Antibody, Antineoplastic
Antineoplastic